XCUR · Exicure, Inc.
$1.30
+0.00 (+0.00%)
At close · Sep 2
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Management believes that, given the Company's current cash position, operating plans and forecasted negative cash flows from operating activities over the next twelve months, there is substantial doubt about the Company's ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued. Additional financing will be needed to fund ongoing operations, support of GPCR USA's operations, and exploration of strategic alternatives and pursuing any alternatives that management identifies. Management's plan to alleviate this substantial doubt include pursuing additional equity and/or debt financings, strategic transactions, potential business combination opportunities and other sources of capital. However, there can be no assurance that such plans will be successful.”View the 10-Q filed Aug 14, 2026
Market Cap
$8.44M
Shares
6.55M
XCUR metrics
51 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$1.30
Market cap
$8.44M
Price action
19 metricsPrice change (1W)
+9.2%
Price change (30D)
-17.7%
Price change (3M)
-58.2%
Price change (6M)
-63.4%
Price change (YTD)
-76.0%
Price change (1Y)
-76.8%
Trailing year
Price change (5Y)
—
52-week high
$7.29
52-week low
$1.15
Change from 52-week high
-82.2%
Change from 52-week low
+13.0%
Annualized volatility
113.9%
Beta
0.5
RSI (14D)
42.6
Price vs SMA 50
-21.7%
Price vs SMA 200
-63.8%
Avg volume (3M)
400,695
Relative volume
0.0
Average dollar volume
$681,798
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
6.55M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
8.8
reciprocal yield 11.4%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-96.6%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
8.3×
reciprocal yield 12.0%
EV / revenue historical average (5Y)
8.3×
reciprocal yield 12.0%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$7.34M
Net income (TTM)
−$8.28M
Trailing 12 months
Diluted EPS (TTM)
$-1.34
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.9%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-847.9%
Return on assets
-72.7%
Debt / equity
—
Current ratio
0.6
EBITDA (TTM)
−$7.14M
Free cash flow (TTM)
—
Quick ratio
0.6
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$1.72M
Total assets
$11.40M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$6.70M
Capital expenditures (TTM)
—
R&D (TTM)
$2.03M
SG&A (TTM)
—
Stock compensation (TTM)
$2,000
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
17
13F filer change QoQ
-1
Institutional ownership
2.1%
Short interest
3 metricsShort interest
0.9%
Latest settlement · 1.4 days to cover
Days to cover
1.4d
Short-squeeze score
35 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged